IMMUCELL CORP /DE/
Close on Oct 19, 2026
- Market cap
- $96.58M
- P/E (TTM)
- 131.4
- Dividend yield
- –
Earnings
Next report expected Nov 12, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 13, 2026 | After market close | $7.20M | $0.20 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 14, 2026 | After market close | $10.40M | $0.21 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 4, 2026 | After market close | $7.63M | $-0.31 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 13, 2025 | After market close | $5.50M | $-0.02 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Jul 9, 2025 | Before market open | $6.40M | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | Apr 8, 2025 | After market close | – | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Jan 10, 2025 | Before market open | $7.80M | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Oct 8, 2024 | After market close | – | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Jul 9, 2024 | After market close | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | Apr 9, 2024 | After market close | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Jan 8, 2024 | After market close | – | – | – |
Press releases
Announcements Immucell filed with the SEC
ImmuCell Announces a 46% Increase in Product Sales in Quarter Three of 2026, Based on Preliminary, Unaudited Sales Results
Results of operations · EX-99.1 to Form 8-K
ImmuCell Announces Unaudited Financial Results for
Results of operations · EX-99.1 to Form 8-K
ImmuCell Announces a 12% Increase in Product Sales in Q2 of 2026 and a 21% Increase in the First Six Months of 2026, Based on Preliminary, Unaudited Sales Results
Results of operations · EX-99.1 to Form 8-K
ImmuCell Announces Unaudited Financial Results
Results of operations · EX-99.1 to Form 8-K
ImmuCell Bolsters its Innovation Strategy with Appointments of
Executive or director change · Other events · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Executive or director change · Other events · EX-99.2 to Form 8-K
ImmuCell Announces a 28.4% Increase in Product Sales in Q1 of 2026, based on Preliminary, Unaudited Sales Results
Results of operations · EX-99.1 to Form 8-K
ImmuCell Announces Unaudited Financial Results
Results of operations · EX-99.1 to Form 8-K
ImmuCell Announces Preliminary, Unaudited Sales Results for Q4 and Full Year of 2025
Results of operations · Material impairment · Other events · EX-99.1 to Form 8-K
ImmuCell Announces Strategic Focus on First Defense® After
Material impairment · Other events · EX-99.1 to Form 8-K
ImmuCell Announces Unaudited Financial Results for
Results of operations · EX-99.1 to Form 8-K
ImmuCell Announces Preliminary, Unaudited Sales Results for Q3 of 2025
Results of operations · EX-99.1 to Form 8-K
PRESS RELEASE OF IMMUCELL CORPORATION DATED AUGUST 14, 2025
Results of operations · EX-99.1 to Form 8-K
PRESS RELEASE OF IMMUCELL CORPORATION DATED JULY 9, 2025
Results of operations · EX-99.1 to Form 8-K
PRESS RELEASE OF IMMUCELL CORPORATION DATED JUNE 25, 2025
Other events · EX-99.1 to Form 8-K
PRESS RELEASE OF IMMUCELL CORPORATION DATED MAY 14, 2025
Results of operations · EX-99.1 to Form 8-K
PRESS RELEASE OF IMMUCELL CORPORATION DATED APRIL 8, 2025
Results of operations · EX-99.1 to Form 8-K
PRESS RELEASE OF IMMUCELL CORPORATION DATED FEBRUARY 25, 2025
Results of operations · EX-99.1 to Form 8-K
PRESS RELEASE OF IMMUCELL CORPORATION DATED JANUARY 16, 2025
Other events · EX-99.1 to Form 8-K
PRESS RELEASE OF IMMUCELL CORPORATION DATED JANUARY 9, 2025
Results of operations · EX-99.1 to Form 8-K
PRESS RELEASE OF IMMUCELL CORPORATION DATED NOVEMBER 13, 2024
Results of operations · EX-99.1 to Form 8-K
PRESS RELEASE OF IMMUCELL CORPORATION DATED OCTOBER 8, 2024
Results of operations · EX-99.1 to Form 8-K
PRESS RELEASE OF IMMUCELL CORPORATION DATED AUGUST 13, 2024
Results of operations · EX-99.1 to Form 8-K
PRESS RELEASE OF IMMUCELL CORPORATION DATED JULY 9, 2024
Results of operations · EX-99.1 to Form 8-K
PRESS RELEASE OF IMMUCELL CORPORATION DATED JUNE 5, 2024
Other events · EX-99.1 to Form 8-K
PRESS RELEASE OF IMMUCELL CORPORATION DATED MAY 14, 2024
Results of operations · EX-99.1 to Form 8-K
PRESS RELEASE OF IMMUCELL CORPORATION DATED APRIL 9, 2024
Results of operations · EX-99.1 to Form 8-K
PRESS RELEASE OF IMMUCELL CORPORATION DATED FEBRUARY 27, 2024
Results of operations · EX-99.1 to Form 8-K
PRESS RELEASE OF IMMUCELL CORPORATION DATED JANUARY 8, 2024
Results of operations · EX-99.1 to Form 8-K
PRESS RELEASE OF IMMUCELL CORPORATION DATED NOVEMBER 13, 2023
Results of operations · EX-99.1 to Form 8-K
IMMUCELL CORPORATION DATED OCTOBER 5, 2023
Results of operations · EX-99.1 to Form 8-K
PRESS RELEASE OF IMMUCELL CORPORATION DATED AUGUST 10, 2023
Results of operations · EX-99.1 to Form 8-K
PRESS RELEASE OF IMMUCELL CORPORATION DATED JULY 11, 2023
Results of operations · EX-99.1 to Form 8-K
PRESS RELEASE OF IMMUCELL CORPORATION DATED JUNE 28, 2023
Regulation FD disclosure · EX-99.1 to Form 8-K
PRESS RELEASE OF IMMUCELL CORPORATION DATED MAY 11, 2023
Results of operations · EX-99.1 to Form 8-K
PRESS RELEASE OF IMMUCELL CORPORATION DATED APRIL 5, 2023
Results of operations · EX-99.1 to Form 8-K
PRESS RELEASE OF IMMUCELL CORPORATION DATED FEBRUARY 21, 2023
Results of operations · EX-99.1 to Form 8-K
PRESS RELEASE OF IMMUCELL CORPORATION DATED JANUARY 9, 2023
Results of operations · EX-99.1 to Form 8-K
PRESS RELEASE OF IMMUCELL CORPORATION DATED NOVEMBER 21, 2022
Results of operations · EX-99.1 to Form 8-K
PRESS RELEASE OF IMMUCELL CORPORATION DATED NOVEMBER 10, 2022
Results of operations · Prior financials no longer reliable · EX-99.1 to Form 8-K